NIIMBL Funds Eight New Biopharma Technology and Workforce Projects
NIIMBL has selected eight new member-led technology and workforce development projects totaling $9.7 million in funding and co-investment through its Project Call 9.1, announced in a press release. The initiative involves 39 participating organizations focused on improving domestic biopharmaceutical manufacturing and workforce capabilities.
The technology projects address areas such as process analytics, AI and machine learning for process optimization, and new protein expression platforms for advanced therapeutics. Participants include universities and industry partners such as Michigan Technological University, University of Delaware, Massachusetts Institute of Technology, and several major biopharma companies.
Three workforce projects aim to expand interest in biopharmaceutical manufacturing careers and develop an AI-ready workforce. These include initiatives led by the University City Science Center, the National Center for Therapeutics Manufacturing at Texas A&M University, and The Wistar Institute.
Since its launch in 2017, NIIMBL has supported 230 technical and workforce projects totaling more than $216 million. The institute operates as part of Manufacturing USA, funded through a cooperative agreement with the National Institute of Standards and Technology.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Enterprise
Sep 11 Evergreen Digital Media Invests in Adwave and Licenses AI Ad Platform Sep 11 Rime to Power Dialpad Voice AI Products Sep 11 Ultima Genomics and NVIDIA Collaborate on Pangenome Sequencing Analysis Sep 11 Zettabyte and Raku Plan Renewable Energy AI Data Centers in Asia Sep 11 DCM Services and AKUVO Partner on Estate RecoveryMore from Life Sciences
Sep 12 Aignostics Opens Early Access to PathoSearch Sep 11 Ultima Genomics and NVIDIA Collaborate on Pangenome Sequencing Analysis Sep 11 UrgentIQ Raises $15 Million for AI Clinical Workflows Sep 11 Penguin Ai Launches Revenue Cycle AI Platform Sep 11 MegazoneCloud Builds Quality Assurance AI Agent for Hanmi PharmaceuticalLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
NOV8TIV Launches N8IQ Technology Assessment for AI Readiness
Sunthetics Joins $19.5M NSF Autonomous Lab Initiative
Cognizant to Implement Benchling AI Platform for Kyowa Kirin Research Sites
LGNDX Gets U.S. Air Force Contract for Defense Acquisition Platform
HealthCatalyst Northwest Arkansas Names Seven Startups for Community Pilots
Daily AI Brief: the AI news that matters, in your inbox.